Inhibitors of metallo-beta-lactamases

0 avis

Inhibitors of metallo-beta-lactamases

Archive ouverte

Hernandez, Jean-François | Gavara, Laurent | Docquier, Jean-Denis | Sevaille, Laurent | Legru, Alice

Edité par CCSD -

The present invention relates to compounds that function as inhibitors of metallo-beta-lactamases (MBL). The present invention also relates to pharmaceutical compositions comprising such MBL inhibitors, and uses thereof in the treatment of bacterial infections. More generally, the present invention finds applications in any field wherein microorganism-producing MBL must be removed.

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Inhibition of metallo-beta-lactamases (MBLs) to fight the bacterial resistance to beta-lactam antibiotics.

Archive ouverte | Legru, Alice | CCSD

International audience. Bacterial resistance to antibiotics is a highly worrying threats to public health and the risk of return to the pre-penicillin era is real. In 2017, WHO has published a Global priority list o...

1,2,4-Triazole-3-thione compounds potently inhibit VIM and NDM-1 metallo-beta-lactamases and re-sensitize multi-resistant clinical isolates to meropenem

Archive ouverte | Hernandez, Jean-François | CCSD

International audience. Introduction et objectifsMetallo-β-lactamases (MBLs) are increasingly involved as a major mechanism of resistance to carbapenems in relevant opportunistic Gram-negative pathogens. Unfortunate...

Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical Isolates

Archive ouverte | Legru, Alice | CCSD

International audience. Metallo-β-lactamases (MBLs) contribute to the resistance of Gram-negative bacteria to carbapenems, last-resort antibiotics at hospital, and MBL inhibitors are urgently needed to preserve thes...

Chargement des enrichissements...

Syracuse